Pushing the limits of immune-related response: a case of “extreme pseudoprogression”

• Main Authors: Wong, A.S, Thian, Y.-L, Kapur, J, Leong, C.-N, Kee, P, Lee, C.-T, Lee, M.B
• Other Authors: DIAGNOSTIC RADIOLOGY
• Format: Article
• Published: Springer Science and Business Media Deutschland GmbH 2020
• Subjects: alkaline phosphatase; axitinib; calcium; creatinine; denosumab; everolimus; gabapentin; hemoglobin; interleukin 2; lactate dehydrogenase; nivolumab; pazopanib; prednisolone; sunitinib; tramadol; antineoplastic agent; monoclonal antibody; programmed death 1 receptor; acute kidney failure; adult; anemia; antiangiogenic therapy; Article; backache; bone metastasis; brain metastasis; calcium blood level; cancer immunotherapy; cancer palliative therapy; cancer radiotherapy; cancer regression; case report; clinical article; computer assisted tomography; creatinine blood level; deterioration; disease course; drug dose reduction; drug megadose; dyspnea; Eastern Cooperative Oncology Group score; echography; edema; erythrocyte transfusion; external beam radiotherapy; extreme pseudoprogression; functional status assessment; general condition improvement; hematuria; hemodialysis; hemolysis; home care; hospice care; human; hypercalcemia; hyperkalemia; immune related response criteria; male; middle aged; oliguria; oncogenesis and malignant transformation; outcome assessment; priority journal; renal cell carcinoma; response evaluation criteria in solid tumors; side effect; single drug dose; spine metastasis; systemic therapy; terminal care; thorax radiography; treatment response; tumor volume; urine volume; antagonists and inhibitors; disease exacerbation; immunology; immunotherapy; kidney tumor; pathology; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/179031
• Institution: National University of Singapore

10.1007/s00262-018-2167-3